Type 1 IFNs, innate cytokines with important effector and immunomodulatory properties, are rapidly induced in the acute phase of many virus infections; however, this is generally a transient response that is not sustained during virus persistence. To gain insight into mechanisms that can contribute to down-regulation of type 1 IFN production during virus persistence, we analyzed type 1 IFN production during acute and chronic lymphocytic choriomeningitis virus (LCMV) infection. High-level type 1 IFN production was transiently up-regulated in cells including plasmacytoid and conventional dendritic cells (DCs) following LCMV infection of mice, but LCMV persistence was associated with only low-level type 1 IFN production. Nonetheless, chronically infected mice were able to up-regulate type 1 IFN production in response to TLR3, 7, and 9 ligands, albeit less efficiently than uninfected mice. Splenic DC numbers in mice chronically infected with LCMV were decreased, and the remaining cells exhibited a reduced response to TLR stimulation. LCMV-infected cell lines efficiently up-regulated type 1 IFN production following TLR ligation and infection with a DNA virus, but exhibited a defect in type 1 IFN induction following infection with Sendai, an RNA virus. This block in type 1 IFN production by infected cells, together with abnormalities in DC numbers and functions, likely contribute to the low-level type 1 IFN production in mice chronically infected with LCMV. Impairment of type 1 IFN production may both promote virus persistence and impact on host immunocompetence. Understanding the mechanisms involved may assist in development of strategies for control of virus persistence and superinfection.
T ype 1 IFNs, mainly consisting of the IFN-␣ and -␤ subtypes, are innate antiviral cytokines with pleiotropic effects. They are rapidly induced during the early stages of many viral infections and mediate effector and immunomodulatary functions that directly help to contain viral replication and induce and regulate the activation of innate and adaptive responses (1) . The importance of type 1 IFNs in combating viral infections has been demonstrated in experiments using blocking Abs and in type 1 IFN receptor knock-out mice, where inability to control a number of virus infections was observed (2) (3) (4) (5) (6) , and is also indicated by the fact that many viruses have evolved strategies for blocking type 1 IFN induction and/or impairing its activity (7) (8) (9) (10) (11) .
During acute viral infections, there is typically a rapidly induced transient burst of type 1 IFN production shortly before the peak in viral replication (1) . This type 1 IFN may be derived from multiple sources. Almost every cell type in the body has the capacity to produce type 1 IFN when it becomes infected with a virus. This is stimulated via pattern recognition receptors (PRR) 6 able to detect the presence of viral components such as dsRNA, DNA, or viral nucleopcapsids. For example, retinoic acid-inducible gene-1 (RIG-I), the prototypic member of the RIG-I-like receptor (RLR) family, is an RNA-sensing helicase present in the cytoplasm of most cells that, upon detection of viral ssRNA or dsRNA in the cytoplasm, induces type 1 IFN production through a signaling pathway dependent upon the mitochondrial protein IFN␤-promoter stimulator-1 (12) . The type 1 IFN that is produced can then up-regulate further type 1 IFN expression via the autologous JAK/STAT pathway to amplify the response made (13) . However dendritic cells (DC), chiefly the plasmacytoid DC (pDC) subset, are thought to act as the major source of systemic type 1 IFN production in many acute virus infections (14, 15) . pDCs are specialized type 1 IFNproducing cells in which type 1 IFN expression can be induced via additional pathogen-sensing PRR pathways including those involving TLR7 and 9. These TLRs are expressed in the endocytic compartment of DCs and can be activated by the presence of viral components in the external environment, enabling DCs to produce type 1 IFN in response to a viral infection while not being themselves infected by the virus (16 -19) .
During persistent viral infections that are accompanied by ongoing viral replication, there is constant exposure to type 1 IFNinducing stimuli, but this is not associated with continuous production of high levels of type 1 IFN, e.g., no elevation in systemic type 1 IFN is observed in individuals chronically infected with HIV, hepatitis C, or hepatitis B virus (8, 20, 21) . Possible explanations for this may include down-regulation of type 1 IFN production by host homeostatic mechanisms invoked to prevent detrimental consequences of continuous exposure to high levels of type 1 IFN (22) and/or impairment of type 1 IFN production as a consequence of virus persistence, which may be actively induced by the virus to promote its survival in the host (7, 23, 24) . To gain insight into mechanisms contributing to the regulation of type 1 IFN production in the context of persistent viral replication, we analyzed the type 1 IFN response in mice chronically infected with the natural murine pathogen lymphocytic choriomeningitis virus (LCMV).
LCMV infection of mice is associated with rapid up-regulation of type 1 IFN production (25, 26) , which promotes effective innate and adaptive control of the infection (2, (27) (28) (29) . The cellular sources of type 1 IFN production during acute LCMV infection remain controversial, but are thought to include both pDCs and other cell types (14, 30 -33) . LCMV can cause either an acute infection of mice which is quickly cleared, or establish a chronic infection during which there is ongoing viral replication accompanied by high systemic viral titers; the outcome of infection is dependent on both host factors (e.g., age and immunocompetence) and the infecting virus (isolate, dose, and route of entry) (reviewed in Ref. 34) . Type 1 IFN production in mice chronically infected with LCMV has been less intensively studied, although several reports indicate that, as in human persistent virus infections, there is only a low level of type 1 IFN production during murine chronic LCMV infection (25, (35) (36) (37) .
In this study, we analyzed type 1 IFN production during the course of an acute LCMV infection that is rapidly cleared and an LCMV infection that persists. We found that there was rapid up-regulation of high levels of type 1 IFN expression following LCMV infection of mice, but that this was only a transient response which was rapidly down-regulated, independently of local/systemic viral titers. LCMV persistence was accompanied by only low-level type 1 IFN production, despite the presence of high levels of ongoing viral replication. Nonetheless, chronically infected animals were able to up-regulate type 1 IFN production in response to exogenous TLR stimuli, although they did so less efficiently than uninfected animals. Analysis of mechanisms that may be contributing to the low level of type 1 IFN production in mice chronically infected with LCMV revealed that there was a reduction in the number of splenic pDCs and conventional DCs (cDCs) in these mice, and that those DCs which were present exhibited an impaired capacity to up-regulate type 1 IFN production in response to in vitro stimuli. We also found that LCMV selectively impairs type 1 IFN production in response to itself and to infection with another RNA virus, Sendai, in cells it infects. Together, these mechanisms likely help to promote virus persistence, but they also impact on the immunocompetence of the host, e.g., we showed that chronically infected mice had an impaired capacity to mount a CD8 ؉ T cell response to an unrelated Ag. The implications of these findings for the choice of therapeutic strategy that could be used to control human persistent virus infections and superinfections that may occur in the context of virus persistence is discussed.
Materials and Methods

Mice
Female C57BL/6 mice 8 -12 wk of age supplied by Charles River Laboratories were used for all in vivo experiments. All animal studies were conducted in accordance with U.K. Home Office regulations and were approved by the site ethical review committee.
Viral isolates, growth, and titration
Stocks of LCMV Armstrong 53b (LCMV Arm), a clone triple plaque purified from LCMV Arm CA1371 (38) and LCMV Armstrong Clone 13 (LCMV Cl13), a triple plaque purified variant of Arm derived from spleen cells of an adult BALB/WEHI mouse persistently infected from birth with LCMV Arm (39) , were prepared by growth in BHK cells, and titers were determined by plaque assay on Vero cells as previously described (38) . Influenza strain A/PR/8/34 was obtained from Charles River SPAFAS. HSV type 1 strain DM-21 was originally obtained from Dr. Terry Hill (University of Bristol, Bristol, U.K.) and stocks were prepared and titrated in BHK cells. Sendai virus Z strain, grown in 10-day old embryonated chicken eggs, was a kind gift from Dr. John Macauley (Institute for Animal Health, Compton, Berkshire). Sendai virus RNA levels in infected mice were determined by real-time quantitative RT-PCR (qRT-PCR) using primers and a probe specific for Sendai virus and conditions described previously (40) .
LCMV infection of mice
Mice were infected by i.v. inoculation with 5 ϫ 10 5 PFU of LCMV Arm or 5 ϫ 10 6 PFU of LCMV Cl13 diluted in 200 l serum-free RPMI 1640 medium (Life Technologies) to generate an acute or chronic LCMV infection, respectively. They were housed in category 3 containment facilities and provided with food and water ad libitum. Animals were sacrificed at different timepoints postinfection. Spleens were removed, snap-frozen in liquid nitrogen, and stored at Ϫ80°C before analysis. Blood was collected by cardiac puncture and serum was separated and stored in aliquots at Ϫ80°C. Plaque assays were conducted on the spleen and serum of infected mice to determine infectious virus titers in these compartments.
Quantitation of type 1 IFN subtype mRNA levels by qRT-PCR
Total RNA was purified from snap-frozen spleen samples or cell pellets using the RNeasy Mini RNA Isolation kit (Qiagen). Snap-frozen spleen samples were homogenized in 300 l of RLT buffer with 1% 2-ME per 30 mg tissue. Homogenized tissue or cell pellets stored in 300 l of supplemented RLT buffer were loaded onto a Qiashredder column and centrifuged to shear the genomic DNA, and the RNA was isolated using RNeasy mini column purification, with on-column Dnase 1 cleanup (Qiagen). Where possible, the purity and concentration of the eluted RNA was determined by UV spectroscopy. Three hundred nanograms of total RNA was used as template for qRT-PCR with primers (Sigma-Genosys) and probes (Applied Biosystems) specific for hypoxanthine ribosyl transferase (HPRT), IFN-␤, IFN-␣4 (41) , and all IFN-␣ subtypes except ␣4 (IFN-␣ (non-␣4)) (42) in reverse transcriptase qPCR master mix (Eurogentec). Samples were run and analyzed in duplicate on an ABI Prism 7700 detection system using the recommended cycling conditions. The average cycle threshold (Ct) value (i.e., the PCR cycle number at which amplification products first became detectable) for each IFN type in a given sample was calculated, and values were normalized by subtraction from the Ct value of the housekeeping gene (HPRT), to give the ⌬Ct value. Higher ⌬Ct values thus reflect the presence of increased IFN mRNA levels.
Quantitation of type 1 IFN activity by bioassay
Serum or culture supernatants were assayed for type 1 IFN activity by measuring their ability to confer resistance to encephalomyocarditis virus infection upon L929 cells, using a method based on that previously described (43) . A standard curve of 2-fold serial dilutions of recombinant IFN-␣ (HyCult Biotechology) was set up on each plate. The sensitivity of the assay was ϳ2 log 2 (4)U/ml IFN.
Analysis of response of mice chronically infected with LCMV Cl13 to innate stimuli
Mice infected 3 wk previously with LCMV Cl13 and uninfected control animals were injected by the i.p. route with one of the following TLR stimuli in 200 l PBS: 5 g polyinosinic acid: polycytidylic acid (polyIC) (Sigma-Aldrich), 50 nmoles R848 (InVivoGen), 25 nmoles CpG 1826 (MWG Biotech), or with 800 hemagglutinin units of influenza virus PR8. Three mice per treatment type from both the LCMV Cl13-infected and uninfected groups and one untreated uninfected control animal were sacrificed at timepoints between 6 and 24 h poststimulation and blood and spleens were removed for analysis.
Isolation of splenic DCs
Spleen DCs were obtained using a variation of the method described by Vremec et al. (44) . Nine to ten spleens were pooled and perfused with 200 l per spleen of DNase (Sigma-Aldrich) (325KU/ml):Collagenase (1 mg/ ml, type III) (Worthington Biochemical) diluted in RPMI 1640 with 10% FCS (Invitrogen), 0.1 mM EDTA (pH 7.2), 100U/ml polymyxin B (SigmaAldrich) and 1 g/ml penicillin-streptomycin (P/S) (Institute for Animal Health Media Supplies). Spleens were digested for 30 min and the homogenate was passed through a 0.45-m cell sieve. Cells were resuspended in Nycoprep (1.07g/ml; Invitrogen), layered on Nycoprep, and spun in a Sorvall RT7plus centrifuge at 2000 ϫ g for 20 min. DCs were further enriched using anti-CD11c microbeads (Miltenyi Biotec).
Analysis of splenic DC subsets
Although splenic DCs are frequently identified on the basis of CD11c expression, during the course of infection with LCMV, this marker is upregulated on many non-DC cell types as a result of activation (45) . To enumerate and to isolate total RNA from specific DC populations, positively selected CD11c ϩ DCs were thus stained with anti-CD11c-allophycocyanin, anti-B220-FITC, and a mixture of PE-conjugated anti-CD3, CD19, and DX-5 (all Abs from BD Pharmingen), then sorted using a Mo-Flo cell sorter (DakoCytomation) into PE-negative, CD11c ϩ B220 ϩ (pDCs), and B220 Ϫ (cDC) subsets. Total RNA was isolated from an equivalent number of cells of each type from each group of mice at each timepoint.
Analysis of the response of CD11c
ϩ DCs to in vitro stimulation with TLR ligands
CD11c
ϩ cells isolated from murine spleens and depleted of non-DC CD11c ϩ lymphocytes as described above were seeded at 1 ϫ 10 5 cells per well into a 96-well U-bottom plate in 100 l of medium containing one of the following: no stimulus, polyIC (1, 10, or 100 g/ml), R848 (1, 10, or 100 g/ml), or CpG (20, 200 , or 2000 pmol/ml). After 24 h stimulation at 37°C, the plate was centrifuged at 1200 rpm for 5 min and the supernatant collected and stored at Ϫ80°C before analysis of its IFN content.
Production of LCMV-infected bone marrow-derived DCs (BM-DCs)
Bone marrow progenitor cells were isolated from the hind limbs of C57BL/6 mice and cultured in GM-CSF-supplemented medium to generate BM-DCs as previously described (46) . After 2-3 days in culture, the cells were infected with LCMV Cl13 at a multiplicity of infection (m.o.i.) of 10 in serum-free medium for 1 h at 37°C. Virus was then removed and the cells were plated into 10 cm culture dishes at a concentration of 1 ϫ 10 6 cells/ml in medium supplemented with 20 g/ml GM-CSF and incubated for a further 5 days. At different times postinfection, supernatant was collected from the infected cultures and control uninfected cultures and stored at Ϫ80°C for subsequent analysis of type 1 IFN levels. Immunostaining assays were also performed to determine the proportion of cells infected with LCMV. At the end of the culture period, both infected and uninfected cells were stained with Annexin V-FITC (BD Pharmingen) and analyzed by flow cytometry.
Generation of LCMV-infected cell lines
BALBCl7, a murine fibroblast cell line grown in Eagle's Minimal Essential Medium (Life Technologies), 7% FCS, and 1 g/ml P/S, or a fetal mouse skin-derived DC line (FSDC) (47) grown in RPMI 1640, 10% FCS, 1 g/ml P/S, and polymyxin B were used. Cells were infected with LCMV Cl13 at a m.o.i. of either 0.1 or 10 in 500 l serum-free medium for 1 h at 37°C. Virus was removed and the cells were seeded into 6-well plates at 1 ϫ 10 6 cells per well in 1 ml medium and incubated. At different times postinfection, supernatant was removed and stored at Ϫ80°C for analysis. Cell pellets were collected in RNA lysis buffer (Qiagen) and stored at Ϫ80°C for RNA extraction. Replicate wells of infected cells were maintained in culture and transferred into small flasks when they appeared confluent. They were then passaged twice a week. Immunostaining assays were performed to confirm that the cells were chronically infected with LCMV.
Analysis of type 1 IFN induction in LCMV-infected BM-DCs and cell lines in response to stimulation with TLR ligands or infection with unrelated viruses
Uninfected BM-DCs, BALBCl7 cells, or FSDC cells and cells previously infected with LCMV Cl13 were seeded at 1 ϫ 10 5 cells per well into U-bottom 96-well plates (Corning). After an overnight incubation, cells were stimulated with the TLR ligands polyIC (100 g/ml), R848 (50 g/ ml), CpG 1826 (2 nmol/ml), or medium only for 24 h. Alternatively, cells were infected with Sendai virus at an m.o.i. of 10 or HSV at an m.o.i. of 5 for 1 h, after which the virus was removed and replaced with growth medium and the plates incubated until 4 or 18 h postinfection. Following the incubation period, the plates were centrifuged at 200 ϫ g for 5 min in a Sorvall RT7 centrifuge and cells and supernatant were collected as described above and stored at Ϫ80°C before analysis.
In vivo CTL assay
Mice were infected with LCMV Cl13 as described above. Three weeks later, groups of control uninfected and LCMV Cl13-infected mice were immunized i.p. with 500 g OVA protein (Sigma-Aldrich) dissolved in PBS either alone or in the presence of 50 g polyIC. Nine days later, killing of SIINFEKL-coated target cells was assessed using an in vivo CTL assay. In brief, splenocytes from naive, syngeneic C57BL/6 mice were incubated in the presence or absence of 1 nM SIINFEKL peptide for 1 h at 37°C. The cells were then washed extensively with PBS/0.1% BSA. The target and control non-peptide-pulsed populations were labeled with 2 and 0.2 M CFSE (Molecular Probes), respectively, in PBS/0.1% BSA for 7 min. at 37°C. The reaction was stopped with an excess volume of cold PBS/5% FCS before washing twice more in serum-free medium. Target and control populations were counted, mixed at a 1:1 ratio and 2 ϫ 10 7 total cells were injected i.v. into immunized mice. Eighteen hours later, spleens were removed from recipient mice, cell suspensions prepared and cells were analyzed using a FACSCalibur (Becton Dickinson) using CellQuest software (Becton Dickinson). The ratios (R) of peptide-treated and control populations in the spleens were determined. Percentage of cytolysis was calculated using the formula [1 Ϫ (R uninfected /R infected )] ϫ 100.
Statistical analysis
Statistical analyses were performed on Minitab Release 14 software (Minitab). Results were analyzed using a 1-sample t test or an ANOVA using a general linear model with Tukey's pairwise comparison to determine the statistical significance of differences between groups.
Results
LCMV infection of mice is associated with rapid induction of type 1 IFNs, but high levels of type 1 IFNs are not sustained in the context of LCMV persistence
To enable analysis of the type 1 IFN response during acute and chronic LCMV infection, C57BL/6 mice were infected i.v. with either a moderate dose of LCMV Armstrong, or a high dose of LCMV Cl13. As shown in Fig. 1A , both LCMV isolates replicated in systemic sites including the spleen, where infectious virus was detectable from day 1 postinfection, but whereas splenic viral titers peaked at day 2 postinfection in LCMV Arm-infected mice and infectious viral titers fell below the level of detection between 7 and 21 days postinfection, mice infected with LCMV Cl13 became chronically infected, with infectious virus remaining detectable in the spleen and serum for more than 30 days postinfection. Type 1 IFN production over the course of each of these infections was assessed by quantitation of splenic mRNA levels and measurement of type 1 IFN activity in the serum. Samples from uninfected animals were also analyzed in parallel at some timepoints to give insight into baseline levels of type 1 IFN production in uninfected mice housed in the same animal facility. As shown in Fig. 1B , very low levels of IFN-␤, IFN-␣4, and non-␣4 subtypes of IFN-␣ could be detected in the spleen of uninfected mice at all timepoints analyzed. Infection of mice with either LCMV Arm or Cl13 was associated with a very rapid (within 6 h) increase in mRNA levels of each of the type 1 IFN subtypes measured, with peak type 1 IFN mRNA levels being observed at 12-24 h postinfection. In three independent experiments conducted, peak splenic type 1 IFN mRNA levels in LCMV Arm-infected mice were found to be slightly higher than those in LCMV Cl13-infected mice. Notably, splenic type 1 IFN mRNA levels fell sharply between 24 and 48 h postinoculation in mice infected with either LCMV Arm or Cl13, despite the fact that splenic titers of both viruses were increasing at this time. Between 2 and 7 days postinfection, viral titers in the mice infected with LCMV Arm and Cl13 diverged considerably, with LCMV Arm titers dropping markedly while LCMV Cl13 titers initially continued to increase and then underwent a slight decline, but still remained at Ͼ7 log 10 pfu/g spleen on day 7. However splenic type 1 IFN mRNA levels in mice infected with the two viruses were virtually indistinguishable over this time-frame, undergoing a gradual decline toward the baseline levels observed in uninfected animals. Thus, although a burst of type 1 IFN mRNA induction was initially triggered by the presence of infection with either LCMV isolate, splenic type 1 IFN mRNA levels were subsequently down-modulated with kinetics quite distinct from those of splenic viral replication.
Analysis of serum type 1 IFN levels also confirmed that the type 1 IFN response induced following infection of mice with LCMV Arm or LCMV Cl13 exhibited very similar kinetics (Fig. 1C) . In mice infected with either virus, type 1 IFN production was upregulated very rapidly after infection, with levels of activity in the serum reaching a peak within the first 48 h of infection, before peak viral titers were reached. Serum type 1 IFN levels fell rapidly from day 3 onwards in both groups of mice, reaching a very low level similar to that detected in control uninfected animals by day 7 postinfection.
By day 21 postinfection, when infectious virus was no longer detectable in the spleen of mice initially infected with LCMV Arm, type 1 IFN mRNA levels in these animals were lower than those in control uninfected animals. However, in LCMV Cl13-infected mice where infection persisted, IFN-␤ and IFN-␣4 mRNA levels remained slightly elevated (Fig. 1B) . In line with this, mice chronically infected with Cl13 were not found to have elevated levels of type 1 IFN activity in the serum at chronic timepoints (Fig. 1C) , or exhibited a low-level elevation in serum activity (Fig. 2) despite the presence of high viral titers in the serum.
Together, these observations showed that type 1 IFN production is rapidly induced following infection of mice with LCMV Arm or Cl13, but then quickly declines, not due to elimination of the IFNinducing stimulus, but rather as a result of host homeostatic control and/or effects of infection (with either LCMV isolate) on type 1 IFN production. Persistence of LCMV Cl13 was associated with a slight elevation of IFN-␤ and IFN-␣ mRNA levels in the spleen although little or no elevation was detected in type 1 IFN activity in the serum. The mechanism(s) responsible for the initial downmodulation of high level type 1 IFN production in the presence of ongoing stimulation may thus be sustained during chronic LCMV infection, or different mechanisms may be involved at later times.
Chronically infected mice retain the capacity to up-regulate type 1 IFN production in response to exogenous stimuli, although the fold increase in type 1 IFN levels is lower than in uninfected animals
To provide insight into the nature of the block or defect in type 1 IFN production in mice chronically infected with LCMV Cl13, the ability of chronically infected mice to respond to a selection of exogenous type 1 IFN-inducing stimuli was addressed. Uninfected animals and mice chronically infected with LCMV Cl13 were inoculated i.p. with ligands for TLR3 (polyIC), TLR7 (R848), TLR9 (CpG 1826 DNA), or with influenza PR8, which would activate TLR7 and/or the intracellular infection sensing pathway (18, 48) , and type 1 IFN mRNA levels in the spleen and type 1 IFN activity in the serum were monitored.
In uninfected mice, inoculation of the TLR3, 7, and 9 ligands polyIC, R848 and CpG 1826 DNA induced up-regulation of all type 1 IFN mRNA subtypes in the spleen, with maximal type 1 IFN mRNA levels being reached by 12 h postinfection and levels remaining elevated at 24 h poststimulation. Splenic IFN-␤ mRNA levels in control animals and mice inoculated 12 h previously with each of the TLR ligands are shown in Fig. 2A ; each TLR ligand elicited a response of approximately equal magnitude, with IFN-␤ levels being ϳ7⌬Ct units higher than those in control mice. Likewise, all three TLR ligands elicited a strong increase in the levels of bioactive type 1 IFN present in the serum (Fig. 2B) . The levels of type 1 IFN mRNA detected in the spleen and bioactivity detected in the blood of LCMV Cl13-infected mice at 12 h postinoculation with each of the TLR ligands were very similar to those in uninfected mice responding to the same stimuli (Fig. 2, A and  B) . However, the uninfected mice up-regulated type 1 IFN production to a greater extent than the infected animals, as the baseline levels of IFN-␤ transcripts in the spleen of uninfected mice were lower than those in the spleen of Cl13-infected animals and low levels of type 1 IFN activity could be detected in the serum of Cl13-infected but not uninfected mice before stimulation.
Uninfected mice also generated a strong type 1 IFN response following inoculation of influenza virus, with type 1 IFN mRNA levels in the spleen and activity levels in the blood at 12 h postinfection (when the response was maximal), being slightly higher than those reached in mice inoculated with TLR ligands. LCMV Cl13-infected mice also up-regulated type 1 IFN production in response to inoculation with influenza virus, although the maximal levels of splenic type 1 IFN mRNA and serum type 1 IFN activity recorded in these animals were appreciably lower than those in uninfected mice (Fig. 2, A and B) . Analysis by qRT-PCR using primers that detected influenza PR8 genomic RNA, i.e., both virion RNA and genome-sense RNA generated in infected cells, indicated that less influenza virus was present in the spleens of LCMV Cl13-infected mice than control influenza-infected animals at 12 and 24 h postinoculation (data not shown), which may have been a consequence of reduced virion trapping in the spleen and/or impaired viral replication in the LCMV Cl13-infected animals. It was unclear whether the reduced type 1 IFN response elicited in LCMV Cl13-infected mice following inoculation with influenza virus was a consequence of impaired responsiveness and/or a lower magnitude stimulus. Nonetheless, this series of experiments showed that mice chronically infected with LCMV Cl13 retained the capacity to up-regulate type 1 IFN production to at least some extent in response to stimulation with TLR3, 7, or 9 ligands and inoculation with influenza virus, although the fold-increase in type 1 IFN levels was of a lower magnitude than that in uninfected animals.
Type 1 IFN is produced by pDCs and cDCs in acute LCMV infection
DCs have been identified as important producers of type 1 IFNs during many virus infections, with pDCs being implicated as the source of much of the type 1 IFN found in serum in a number of infections (although this remains controversial for LCMV; Ref. 31) . To gain insight into the roles of pDCs and cDCs in type 1 IFN production during the early and late phases of LCMV infection, a kinetic analysis of type 1 IFN mRNA levels in pDC and cDC subsets isolated from the spleens of LCMV Arm or Cl13-infected mice was conducted. The levels of IFN-␤, IFN-␣ 4, and IFN-␣ (non-␣4) mRNA in each subset were determined by qRT-PCR. As levels of all the type 1 IFN transcripts measured changed in parallel with very similar kinetics, only the IFN-␤ data is shown (Fig.  3A) . There was no appreciable difference in type 1 IFN mRNA up-regulation in DCs in the acute phase of infection with LCMV Arm or Cl13. IFN-␤ transcripts were strongly up-regulated in the pDC subset within 12 h of infection of mice with either virus. By day 1 postinfection they had begun to decline; a sharper drop was observed by day 2, and by day 7 postinfection they had returned to baseline. The kinetics of type 1 IFN mRNA upregulation in the cDC population were slightly slower, with some increase in IFN-␤ transcripts being observed by 12 h postinfection (although not as marked an increase as occurred in pDCs), maximum levels being reached on day 1 postinfection, and then transcript levels declining again by day 2 and dropping further by day 7 postinfection. In mice infected with LCMV Arm, IFN-␤ mRNA levels in both pDCs and cDCs were below the limit of detection by 3 wk postinfection, i.e., were lower than those in DCs from uninfected mice, parallel to the results of analysis of total splenic mRNA (Fig. 1B) . In mice chronically infected with LCMV Cl13, a low level of IFN-␤ mRNA could be detected in the pDC subset, while IFN-␤ mRNA levels in cDCs were below the level of detection. Notably, IFN-␤ mRNA levels in total splenic tissue of chronically infected mice were higher than those in the spleen of the uninfected mice, suggesting that a cell type other than pDCs or cDCs may constitute the main source of type 1 IFN production in mice chronically infected with LCMV Cl13.
These results show that both pDCs and cDCs contribute to type 1 IFN production during the acute phase of LCMV infection. Type 1 IFN production was induced very rapidly in pDCs and with somewhat slower kinetics in cDCs following infection of mice with LCMV Arm or Cl13; however, high levels of type 1 IFN mRNA expression were not sustained in these DC subsets. Instead, the response was quickly down-regulated, and remained low/undetectable in mice chronically infected with LCMV Cl13, despite constant exposure of the DCs in these animals to virus.
Changes in splenic DC numbers in LCMV-infected mice
Having demonstrated that type 1 IFNs are produced by DCs in LCMV-infected mice, additional experiments were conducted to address changes in splenic pDC and cDC numbers in mice infected with LCMV Arm and Cl13. As shown in Fig. 3B , the number of pDCs (CD11c ϩ B220 ϩ DCs) did not change appreciably during the first few days following infection with LCMV Arm, consistent with observations we previously made in a study of mice infected i.p. with this virus (32) . However, at 3 wk postinfection, the number of pDCs in the spleen was reduced compared with that in uninfected mice. By contrast, as we previously observed in mice infected i.p. with LCMV Arm (32), the number of cDCs (CD11c ϩ B220 Ϫ ) in the spleen was reduced by day 2 postinfection, but had returned to normal by 3 wk postinfection.
The number of pDCs in the spleens of LCMV Cl13-infected mice did not change appreciably within the first 24 h postinfection, but was reduced by day 2 postinfection and was still more profoundly decreased in the chronic phase of infection. Splenic cDC numbers in Cl13-infected mice were also reduced by day 2 postinfection and again remained lower than cDC numbers in uninfected mice during chronic infection, although their numbers were not as severely depressed at 3 wk postinfection as those of the pDC subset. These results show that changes in splenic DC numbers took place as early as day 2 following infection with Arm or Cl13 and that the number of splenic pDCs and cDCs remained depressed in Cl13-infected mice during the chronic phase. Notably, phenotypic analysis indicated that the low numbers of pDCs and cDCs that were present in the spleen of mice chronically infected with Cl13 exhibited an activated phenotype, expressing elevated levels of MHC class I, CD86, CD80, and CD40 (data not shown).
Splenic DCs isolated from mice chronically infected with LCMV Cl13 exhibit a reduced response to in vitro stimulation with TLR3, 7, and 9 ligands
The observation that DC numbers in mice chronically infected with LCMV Cl13 were reduced suggested that this may contribute to the impairment in type 1 IFN production in these animals. Additional experiments were conducted to investigate whether the existing DCs also exhibited an impaired capacity to respond to TLR stimuli. CD11c ϩ cells were isolated from the spleens of uninfected mice and mice chronically infected with LCMV Cl13, depleted of non-DC CD11c ϩ subsets, and stimulated with polyIC, R848, or CpG 1826 DNA, then type 1 IFN activity in the supernatant was analyzed after an overnight incubation (Fig. 4) . CD11c ϩ DCs from Cl13-infected mice were found to produce type 1 IFN in response to all the TLR stimuli tested, although the levels produced by these cells were lower than those made by DCs from uninfected mice. Statistical analysis using a one-sample t test showed that there was a significant difference between levels of type 1 IFN produced by DCs from uninfected and LCMV-infected mice in response to stimulation with polyIC ( p ϭ 0.03), R848 ( p ϭ 0.05), and CpG DNA ( p ϭ 0.03). Notably, the difference between the ability of DCs from uninfected and LCMV Cl13-infected mice to produce type 1 IFN in response to TLR ligation was most pronounced at suboptimal TLR ligand concentrations (supplementary Fig. 1) . 7 Both the reduction in DC numbers and the impaired capacity of DCs to produce type 1 IFN in response to TLR stimulation may thus contribute to the impairment in type 1 IFN production in mice chronically infected with LCMV Cl13.
Cell lines chronically infected with LCMV do not continuously produce type 1 IFN, but chronically infected DC cell lines produce type 1 IFN efficiently in response to certain stimuli
To gain insight into mechanism(s) that may underlie the impairment observed in the ability of DCs from mice chronically infected with LCMV to produce type 1 IFN in response to TLR stimuli, the 7 The online version of this article contains supplementary material. ϩ DCs isolated by positive selection and depletion of contaminating CD11c ϩ lymphocytes from uninfected mice and mice chronically infected with LCMV Cl13 were cultured overnight in medium alone (Unstim) or with polyIC (10 g/ml), R848 (10 g/ml) or CpG 1826 DNA (200 pmol/ml). Type 1 IFN activity in the supernatant was measured by bioassay. The data shown are the mean of results obtained in three independent experiments using cells pooled from groups of three to ten mice; the error bars indicate 1 SE above the mean. Statistical analysis using a one-sample t test showed a significant difference (p Ͻ 0.05) between the levels of type 1 IFN activity produced by DCs from uninfected and Cl13-infected mice in response to stimulation with each of the TLR ligands tested.
effects of chronic LCMV infection on the type 1 IFN response were studied in vitro. One series of experiments was conducted using BM-DCs. BM-DCs were generated by in vitro culture of bone marrow progenitor cells in GM-CSF-containing medium. Infection of these cells with LCMV Cl13 on day 2 (or day 5, data not shown) of the culture period resulted in viral infection of the majority of cells, as evidenced by staining with an Ab against the viral nucleoprotein (NP) (supplementary Fig. 2A ). In line with observations made in vivo, infection of these cultures was associated with induction of type 1 IFN production, with supernatant levels of type 1 IFN activity peaking at 2-3 days postinfection (supplementary Fig. 2B ). This was accompanied by up-regulation of activation markers including MHC class II on the BM-DCs, suggesting that they were undergoing maturation (data not shown). However, by day 5 postinfection, the infected cells were also strongly positive for Annexin V (supplementary Fig. 2C ), indicating that they were entering an apoptotic state. The poor in vitro survival of these cells meant that efforts to use BM-DCs in experiments to address the ability of LCMV-infected DCs to produce type 1 IFN in response to TLR ligation or infection with other viruses were unsuccessful. Further work was thus conducted using an immortalized DC line, FSDC.
Initial experiments showed that infection of FSDC cells, and also other cell lines including the murine fibroblast cell line BALBCl7, with LCMV Cl13 resulted in generation of a fully viable chronically infected population of cells, the majority of which were infected with LCMV as judged by immunostaining with an LCMV NP-specific Ab (data not shown). Type 1 IFN production by both FSDC cells and BALBCl7 cells was assessed at different times following infection by bioassay. Interpretation of results was complicated by the fact that type 1 IFN production by uninfected FSDC cells fluctuated somewhat over time, perhaps reflecting a response to manipulation or medium change during passage and/or changes in cell confluence. However, while little elevation in supernatant type 1 IFN levels was observed following LCMV infection of BALBCl7 cells, LCMV infection of FSDC cells was found to be associated with a transient elevation in supernatant type 1 IFN levels that peaked ϳ2 days postinfection (data not shown).
Additional experiments were conducted to address whether FSDC cells infected with LCMV were able to produce type 1 IFNs in response to infection with unrelated viruses or stimulation with TLR ligands. FSDC cells which had been infected at least 30 days previously with LCMV were infected with a second virus, either Sendai (an RNA virus) or HSV (a DNA virus), and the type 1 IFN response induced by the second infection was measured 18 h later. Uninfected cells responded to infection with either Sendai virus or HSV by up-regulating expression of IFN-␤, IFN-␣4, and other IFN-␣ subtypes, with infection by HSV eliciting a stronger response than infection with Sendai (Fig. 5A) . In cells chronically infected with LCMV, HSV also induced a strong up-regulation of all type 1 IFN subtypes, although the levels produced were slightly lower than those made by similarly exposed non-LCMV-infected cells. However, when cells chronically infected with LCMV were infected with Sendai virus, although there was some up-regulation of all subtypes of type 1 IFN, the levels produced were lower at 18 h postinfection than those made by Sendai-infected control cells for all subtypes measured.
To exclude the possibility that the chronically infected cells had a pre-existing antiviral state and so were resistant to a further infection with Sendai, qRT-PCR assays were used to quantify Sendai virus NP RNA transcripts in uninfected and chronically infected cells at different timepoints following infection with Sendai virus. The results indicated that both uninfected and LCMV-infected cells were infected equally well by Sendai virus (Fig. 5B) . Equivalent levels of Sendai virus NP RNA were detected in both cell populations at 4 h postinfection and had increased to a similar extent by 18 h postinfection, indicative of viral replication occurring in a parallel fashion in both control and LCMV Cl13-infected cells. The reduced up-regulation of type 1 IFN observed when LCMV-infected cells were infected with Sendai virus thus reflected an impairment in their ability to respond to this stimulus.
These observations at the IFN transcript level were confirmed by analysis of type 1 IFN activity in the supernatant of cells at 18 h postinfection (Fig. 5C) . In uninfected cells, high levels of type 1 IFN activity were produced in response to infection with Sendai or HSV (ϳ2 11 U/ml), indicating that both viruses stimulated strong type 1 IFN responses. However, whereas the levels of type 1 IFN secreted by uninfected and LCMV-infected cells upon infection with HSV were similar, the levels of type 1 IFN detected in the supernatant of chronically infected cells infected with Sendai virus were significantly lower than those produced by uninfected control cells in response to infection with this virus ( p ϭ 0.0013 assessed by ANOVA using a general linear model). Similar observations were also made in experiments conducted using the fibroblast cell line BALBCl7 (data not shown). Chronically infected cells thus were able to up-regulate type 1 IFN production in response to infection with the DNA virus HSV, but their ability to respond to infection by an RNA virus, Sendai, was impaired.
There are several ways in which cells can sense the presence of viral RNA, including through TLR3 or TLR7, which recognize double stranded or single stranded RNA, respectively, and via a cytoplasmic pathway initiated by activation of helicases such as RIG-I or MDA5 (49) . To assess the ability of cells chronically infected with LCMV Cl13 to respond to TLR stimuli, LCMVinfected FSDC cells were stimulated with polyIC, R848, or CpG1826. As shown in Fig. 5C , there was no difference in the level of type 1 IFN induced by the synthetic TLR ligands in uninfected and chronically infected FSDC cells, indicating that the TLR 3, 7, and 9 pathways were not impaired in cells chronically infected with LCMV. Together, these results indicate that LCMV infection does not directly impair the ability of DCs to up-regulate type 1 IFN production in response to TLR ligation or infection with a DNA virus, HSV, but suggest that there could be an impairment in the response to stimuli that trigger type 1 IFN activation of cytoplasmic RNA helicases such as RIG-I. The latter observation is consistent with the recent finding that LCMV impairs nuclear translocation of IFN regulatory factor (IRF)-3 in the cells it infects to block the production of type 1 IFN that its own nucleic acids would otherwise elicit (50) .
Chronically infected mice mount a CTL response of reduced magnitude following immunization with OVA
Type 1 IFNs possess adjuvant properties, as demonstrated in the OVA-immunization model, where robust CTL responses against the soluble OVA Ag only develop when the Ag is co-administered with adjuvants such as type 1 IFNs or a type 1 IFN-inducing stimulus such as polyIC (51) . A final series of experiments were conducted using this model system to determine whether the diminished capacity of mice chronically infected with LCMV to produce type 1 IFNs in response to type 1 IFN-inducing stimuli affects their ability to mount an immune response to unrelated Ags. Chronically infected C57BL/6 mice were immunized with OVA in the presence or absence of polyIC and the OVA-specific effector response elicited was analyzed 10 days later using an in vivo CTL assay, measuring the percentage cytolysis of autologous target cells loaded with the SIINFEKL peptide, which is an immunodominant epitope in the OVA Ag in H-2 b mice. As shown in Fig. 6 , immunization with OVA protein alone did not induce SIINFEKL-specific effector responses in uninfected mice or in mice chronically infected with LCMV Cl13. Administration of polyIC, a type 1 IFN-inducer, in combination with OVA during immunization greatly enhanced the effector response in uninfected mice, generating a high level of SIINFEKL-specific cytotoxic activity. Some cytotoxic activity was also generated in chronically infected mice, although this was not as strong as was observed in their uninfected counterparts. This indicates that the diminished capacity of chronically infected mice to produce type 1 IFN upon stimulation with TLR ligands does not abolish the ability of these animals to mount an effector CTL response when subsequently exposed to unrelated Ags, although the reduction in type 1 IFN production and/or other immunological abnormalities in these animals do result in an impairment in CTL induction.
Discussion
In this study, we analyzed type 1 IFN production during the acute and chronic phases of LCMV infection of mice, and addressed mechanisms that may contribute to the low level of type 1 IFN production in chronically infected animals. Infection of mice with either LCMV Arm (which was subsequently cleared) or LCMV Cl13 (which establishes a chronic infection) was associated with rapid induction of a strong systemic type 1 IFN response. However, this response was short-lived, with splenic IFN mRNA and serum IFN bioactivity levels starting to fall while virus titers were still increasing in both infections. Further, chronic LCMV infection was associated with only a low level of ongoing type 1 IFN production, despite the presence of high viral titers. Chronically infected mice nonetheless retained some capacity to produce type 1 IFN in response to TLR3, 7, and 9 stimuli, although the level of IFN mRNA up-regulation was lower than in uninfected animals. Splenic pDCs (and to a lesser extent cDCs) up-regulated type 1 IFN mRNA expression in acute LCMV infection with kinetics consistent with them acting as a source of systemic type 1 IFN production in early infection, and pDCs were also implicated as one of the cellular sources of type 1 IFN production in mice chronically infected with LCMV Cl13. Splenic DC numbers were reduced during chronic LCMV infection, which was likely one of the factors that contributed to the low level of type 1 IFN production in chronically infected mice. The remaining DCs also displayed an impaired response to TLR stimulation. LCMV-infected cells exhibited a defective capacity to up-regulate type 1 IFN production in response to infection with Sendai virus, but remained responsive to TLR stimuli. The reduced response of DCs from LCMV-infected mice to TLR ligation was thus probably not due to infection of these cells but may have been a consequence of persistent exposure to activating stimuli.
Rapid induction of type 1 IFN production in acute LCMV infection has been previously documented (e.g., Refs. 26, 32, 33, 52) and in this study, we showed that a very similar response is induced in the acute phase of LCMV infections that go on to persist. Type 1 IFNs may be induced by several cellular pathways. These include the RLR family-dependent pathways present in most cell types that enable them to up-regulate type 1 IFNs following infection by sensing nonself nucleic acids in the cytoplasm (53) and the TLR-dependent pathways that enable cells expressing these PRRs, including pDCs, to up-regulate type 1 IFN production following recognition of viral components without the need to be infected. Both pathways are amplified in an autocrine fashion by signaling via the type 1 IFN receptor. LCMV was recently shown to inhibit production of IFN-␤ in the cells it infects via a mechanism that involves a block in nuclear translocation of IRF-3 mediated by the viral nucleoprotein (50), which is expressed at high levels in mice chronically infected with LCMV Cl13. This is a conserved function exhibited by nucleoproteins of most arenaviruses, suggesting it favors virus persistence in vivo (54) . Infected cells are therefore unlikely to be a major source of type 1 IFN production in vivo, in support of which serum IFN-␤ levels in LCMV-infected IFN␤-promoter stimulator-1-deficient mice were found to be very similar to those in LCMV-infected control animals, although there was some decrease in IFN-␣ levels (33) . Instead, type 1 IFN is probably mainly derived from uninfected cells recognizing viral components by means of TLRs and other PRRs. Consistent with this, some (33) but not all (55) studies have shown that LCMV infection of mice lacking MyD88, an adaptor molecule involved in transduction of signals from TLRs including TLR7 and 9 into the nucleus, is associated with a reduced type 1 IFN response. DCs, in particular the pDC subset, act as the major source of circulating type 1 IFN production in many acute viral infections. The role of pDCs in type 1 IFN production in acute LCMV infection is controversial, as depletion of cells expressing Ly6C, a marker expressed by pDCs but not cDCs, did not affect type 1 IFN production in LCMV-infected mice (14, 15) . However, we showed both in this and a previous study in mice acutely infected with LCMV Arm by the i.p. route (32) , that splenic pDCs are induced to produce type 1 IFN very rapidly after LCMV infection, with cDCs contributing to the response with delayed kinetics. Support for the concept that pDCs do constitute the predominant source of type 1 IFN production within the spleen after LCMV infection was also provided by a recent study using novel transgenic Ifn-a6-GFP reporter mice (33) . Therefore, the initial burst of type 1 IFN production observed during infection with both LCMV Arm and LCMV Cl13 may be mainly generated by stimulation of pDCs (with a lesser contribution by cDCs and other cell types) by viral components such as ssRNA (likely recognized via TLR7) or the viral glycoprotein (which may be recognized by other TLR(s)).
In contrast to the high levels of type 1 IFN produced in the acute phase of LCMV infection, little type 1 IFN is produced during chronic LCMV infection. We also showed that chronically infected mice have an impaired ability to up-regulate type 1 IFN in response to TLR stimuli, although some response was induced. Consistent with this, mice chronically infected with LCMV from birth were previously found to respond to polyIC treatment by up-regulating type 1 IFN production and undergoing NK cell activation, although the response induced was reduced compared with that observed in uninfected control animals (35) . There are a number of possible explanations for the very low levels of type 1 IFN production in mice chronically infected with LCMV Cl13. Firstly, a large reduction in the number of pDCs and also cDCs was observed in chronically infected mice. The mechanisms responsible for the reduction in DC numbers in chronically infected mice are unclear, but our observation that the remaining DCs in these animals were phenotypically activated suggests that DC activation and maturation (mediated by the presence of infection and/or the chronic low-level type 1 IFN production) may reduce the lifespan of these cells, causing pDCs to mature into other DC subsets (56) and/or both DC subsets to undergo activation-associated apoptotic cell death (32) . Consistent with this, we found that BM-DCs underwent activation and apoptosis following in vitro infection with LCMV (supplemental Fig. 2 ). Enhanced DC loss in vivo may be compounded by defects in the rate of replacement of DCs. LCMV infection has been reported to cause profound alterations in hematopoietic differentiation (57) (58) (59) (60) , which are thought to be mediated in large part by cytokines induced in the context of infection. Notably, it has been shown that continuous type 1 IFN production during chronic LCMV infection suppresses the development of bone marrow precursor cells into DC (61) . However, the reduction in DC numbers is probably not the only explanation for the low levels of type 1 IFN produced in chronically infected mice, as we also found that the remaining DCs in these animals exhibit a reduced capacity to up-regulate type 1 IFN production in response to TLR ligation. LCMV Cl13 is a DC-tropic LCMV isolate (50, 62) and during chronic infection, may infect as many as a third of the DCs in the spleen. We thus addressed whether the impairment observed in TLR-stimulated type 1 IFN production by DCs from chronically infected mice may be a consequence of infection of these cells with LCMV. However, although we found that chronic LCMV infection impaired the capacity of a DC line to up-regulate type 1 IFN production following infection with Sendai virus (likely as a consequence of the LCMV nucleoprotein-mediated block in nuclear translocation of IRF-3, which would impede type 1 IFN induction in response to the presence of cytoplasmic Sendai viral RNA via RLR-family pathways; Ref. 50), no effect was observed on the ability of the cells to produce type 1 IFNs in response to TLR3, 7, or 9 stimuli.
The reduced responsiveness of DCs isolated from LCMV-infected mice to TLR ligation may potentially have been a consequence of impaired in vitro survival of these cells; as mentioned above, they were phenotypically activated, and hence may have had a reduced lifespan. Alternatively, their reduced responsiveness may reflect a homeostatic mechanism to limit type 1 IFN-mediated immunopathology. Excessive production of type 1 IFNs and also other proinflammatory cytokines can have detrimental effects on the host, and a number of mechanisms have been described which negatively regulate TLR signaling cascades at different levels, in addition to which there are multiple negative-feedback mechanisms that self-limit TLR-and cytokine-driven responses (22, 63) . The DCs in mice chronically infected with LCMV may have been rendered hyporesponsive to TLR stimulation by the continuous presence of viral components, resulting in a muted response to the TLR stimuli we administered. Although there are high circulating titers of infectious virus in mice chronically infected with LCMV, LCMV is a noncytopathic virus, so the level of TLR ligands present systemically may be relatively low compared with those achieved after administration of exogenous TLR ligands. This could explain why some up-regulation of type 1 IFN production was still elicited following inoculation of chronically infected mice with TLR ligands.
Not only was there little ongoing production of type 1 IFNs in mice chronically infected with LCMV, but we also found that during the acute phase of infection with either LCMV Arm or Cl13, type 1 IFN production occurred only transiently, with levels of splenic mRNA and systemic activity beginning to decline when viral titers were still rising. The mechanisms involved in type 1 IFN down-regulation in acute LCMV infection likely include some or all of those contributing to the low-level IFN production in chronically infected mice. Type 1 IFN mRNA levels in the spleen began to decrease as early as 24 h postinfection, but splenic DC numbers declined with slower kinetics, particularly in mice acutely infected with LCMV Arm. It is thus possible that the initial drop in IFN mRNA levels is largely due to homeostatic negative feedback mechanisms, with activation-associated apoptotic death of DCs (compounded by immunopathogenic destruction of infected cells in Cl13-infected mice) that are inadequately replaced due to compromised homeostasis enhancing the down-regulation of type 1 IFN production at slightly later timepoints (and in fact resulting in type 1 IFN mRNA levels in LCMV Arm-infected animals dropping below the baseline level constitutively present in uninfected animals). The type 1 IFN response induced in the acute phase of most virus infections is very transient; and likewise virus persistence is also generally associated with little or no ongoing type 1 IFN production (8, 20, 21) . The mechanisms we have implicated in down-regulation of type 1 IFN production in LCMV infection, or a subset thereof, may thus be common to many infectious situations.
What are the consequences for the chronically infected host of low level ongoing type 1 IFN production and an impaired ability to up-regulate type 1 IFN production on stimulation? As type 1 IFNs mediate antiviral and immunostimulatory effects, pre-existing levels of this cytokine may confer some level of resistance to other viral infections. For example, the reduced levels of influenza infection we observed in chronically infected animals when the virus was inoculated into the peritoneal cavity, a site where influenza virus replicates poorly, may reflect greater viral resistance as a result of the pre-existing antiviral state in these mice. Conversely, having an impaired ability to up-regulate high levels of type 1 IFN may also impair the host's capacity to combat other infections. Not only will direct control of viral replication be reduced, but type 1 IFN are also critical for the development of robust NK, T, and B cell responses (51, 64, 65) , hence the antiviral activity of these cell types may be affected. In support of this, we observed that mice chronically infected with LCMV Cl13 mounted a CTL response of reduced magnitude following inoculation with a protein Ag together with polyIC, a system where T cell induction occurs in an IFN-dependent fashion. Mice chronically infected with LCMV have also been found to mount impaired immune responses to a variety of other viruses (66, 67) , although other mechanisms (such as the reduction in DC numbers in mice chronically infected with LCMV) may also contribute to the immune deficiency observed in all these systems. These findings highlight the importance of unraveling the mechanisms by which type 1 IFN production is impaired in chronic viral infections, as such information may help to direct the design of more effective immunostimulatory strategies for use in settings of chronic viral persistence.
